HHS notified the institute of the suspension July 17, citing biosafety violations and failure to comply with U.S. regulations. While the U.S. has not found conclusive evidence regarding COVID-19’s origin, it has identified significant breaches in safety and security protocols at the institute and accused China and the lab of impeding investigations into those concerns.
The Wuhan Institute of Virology has received more than $1.4 million in funding from the National Institutes of Health since 2014, though it has not received additional funds since July 2020, according to Bloomberg. The lab may contest the suspension and proposed debarment. However, it will no longer be able to conduct business with the U.S., and affiliations with any organization that does business with the federal government will be closely monitored.
The HHS decision was made independently of the U.S. intelligence community’s ongoing investigations into the emergence of the novel coronavirus in Wuhan in late 2019.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.